Patheon to Sponsor Webinar on Assessing Stability for Shipment of API and Drug Products

Analytical development experts will address questions about regulatory requirements, and stability and shipping studies in a complimentary webinar this month sponsored by Patheon, a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma industries. Hosted by Pharmaceutical Technology, a comprehensive information source for professionals in the global pharmaceutical manufacturing drug development community, the webinar “Stability Assessment for Shipment of API and Drug Products,” will provide guidance on the evaluation of APIs and drug products shipment, and will be held Thursday, May 21, from 11 a.m. to 12 p.m. EDT. 

Patheon recently announced that it is investing more than $3 million to expand its Greenville, N.C. site’s stability testing capabilities. This will allow the facility to offer more than 30,000 cubic feet of state-of-the-art stability storage, and the capabilities to support the largest, most complex projects on small molecule APIs, large molecule biologics and drug substances, solid oral dose drugs, sterile liquid or lyophilized drugs, controlled substances and highly potent compounds.

Webinar participants will hear about the evolving regulatory expectations for stability studies, review challenges in global studies and learn how to improve strategies for biological stability studies. The presenters, Geoff Carr, Ph.D., director, analytical development at Patheon, and Vladimir Golynskiy, Ph.D., senior manager, analytical development at Patheon, will discuss the approaches to assessing stability of biologic APIs and small-molecule drug products throughout expected product shipment. The live webcast will be moderated by Rita Peters, editorial director at Pharmaceutical Technology.

For more information and to register for free, please visit www.pharmtech.com/pt/stability.

Patheon Media Relations

Tel: +1 (919) 210-0986

Email:  tyler.gronbach@patheon.com or media@patheon.com

About Patheon®

Patheon, a business unit of DPx Holdings B.V., delivers a combination of unrivaled quality, reliability and compliance, with a reputation for scientific and technical excellence to customers in the pharmaceutical and biopharma sector. A leading global provider with more than 8,000 employees worldwide, Patheon has a comprehensive set of solutions to help customers of all sizes satisfy complex development and manufacturing needs at any stage of the pharmaceutical development cycle. For more information, visit http://www.patheon.com.

Subscribe